🚀 VC round data is live in beta, check it out!
Veracyte Valuation Multiples
Discover revenue and EBITDA valuation multiples for Veracyte and similar public comparables like HeartFlow, Insight Lifetech, Dr. Lal PathLabs, BGI Genomics and more.
Veracyte Overview
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Founded
2006
HQ
Employees
824
Website
Financials (LTM)
EV
$2B
Veracyte Financials
Veracyte reported last 12-month revenue of $534M and EBITDA of $143M.
In the same LTM period, Veracyte generated $383M in gross profit, $143M in EBITDA, and $70M in net income.
Revenue (LTM)
Veracyte P&L
In the most recent fiscal year, Veracyte reported revenue of $517M and EBITDA of $143M.
Veracyte expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $534M | XXX | $517M | XXX | XXX | XXX |
| Gross Profit | $383M | XXX | $363M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $143M | XXX | $143M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $70M | XXX | $66M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Veracyte Stock Performance
Veracyte has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Veracyte's stock price is $33.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 2.5% | XXX | XXX | XXX | $0.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVeracyte Valuation Multiples
Veracyte trades at 4.3x EV/Revenue multiple, and 16.2x EV/EBITDA.
EV / Revenue (LTM)
Veracyte Financial Valuation Multiples
As of April 18, 2026, Veracyte has market cap of $3B and EV of $2B.
Equity research analysts estimate Veracyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Veracyte has a P/E ratio of 38.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 16.2x | XXX | 16.3x | XXX | XXX | XXX |
| EV/EBIT | 36.5x | XXX | 29.6x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | 6.4x | XXX | XXX | XXX |
| P/E | 38.7x | XXX | 40.5x | XXX | XXX | XXX |
| EV/FCF | 17.0x | XXX | 18.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Veracyte Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Veracyte Margins & Growth Rates
Veracyte's revenue in the last 12 month grew by 12%.
Veracyte's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Veracyte's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Veracyte's rule of X is 54% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Veracyte Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 20% | XXX | 35% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Veracyte Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Veracyte | XXX | XXX | XXX | XXX | XXX | XXX |
| HeartFlow | XXX | XXX | XXX | XXX | XXX | XXX |
| Insight Lifetech | XXX | XXX | XXX | XXX | XXX | XXX |
| Dr. Lal PathLabs | XXX | XXX | XXX | XXX | XXX | XXX |
| BGI Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Veracyte M&A Activity
Veracyte acquired XXX companies to date.
Last acquisition by Veracyte was on XXXXXXXX, XXXXX. Veracyte acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Veracyte
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVeracyte Investment Activity
Veracyte invested in XXX companies to date.
Veracyte made its latest investment on XXXXXXXX, XXXXX. Veracyte invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Veracyte
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Veracyte
| When was Veracyte founded? | Veracyte was founded in 2006. |
| Where is Veracyte headquartered? | Veracyte is headquartered in United States. |
| How many employees does Veracyte have? | As of today, Veracyte has over 824 employees. |
| Who is the CEO of Veracyte? | Veracyte's CEO is Marc A. Stapley. |
| Is Veracyte publicly listed? | Yes, Veracyte is a public company listed on Nasdaq. |
| What is the stock symbol of Veracyte? | Veracyte trades under VCYT ticker. |
| When did Veracyte go public? | Veracyte went public in 2013. |
| Who are competitors of Veracyte? | Veracyte main competitors are HeartFlow, Insight Lifetech, Dr. Lal PathLabs, BGI Genomics. |
| What is the current market cap of Veracyte? | Veracyte's current market cap is $3B. |
| What is the current revenue of Veracyte? | Veracyte's last 12 months revenue is $534M. |
| What is the current revenue growth of Veracyte? | Veracyte revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Veracyte? | Current revenue multiple of Veracyte is 4.3x. |
| Is Veracyte profitable? | Yes, Veracyte is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Veracyte? | Veracyte's last 12 months EBITDA is $143M. |
| What is Veracyte's EBITDA margin? | Veracyte's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Veracyte? | Current EBITDA multiple of Veracyte is 16.2x. |
| What is the current FCF of Veracyte? | Veracyte's last 12 months FCF is $136M. |
| What is Veracyte's FCF margin? | Veracyte's last 12 months FCF margin is 25%. |
| What is the current EV/FCF multiple of Veracyte? | Current FCF multiple of Veracyte is 17.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.